A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

NCT00920946 ↗

Phase 3 Completed 403 enrolled Medivation, Inc. Pfizer · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if Dimebon is safe and effective for the treatment of cognitive impairment in Huntington disease.

Timeline

Start: 2009-07
Primary completion: 2011-07
Completion: —

Outcome

Missed primary endpoint

paper Mini-Mental State Examination score among participants randomized to latrepirdine (1.5-point improvement) did not differ significantly from that among participants randomized to placebo (1.3-point improvement) (P=.39). PMID 23108692 ↗

paper the distribution of the Clinician Interview-Based Impression of Change, plus carer interview did not differ significantly among those randomized to latrepirdine compared with placebo (P=.84). PMID 23108692 ↗

Publications

HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol. 2013 Jan;70(1):25-33. doi: 10.1001/2013.jamaneurol.382.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latrepirdine	Small molecule	20 mg	Oral